U.S. Cancer Patients Travel to China for Faster-Approved Therapies Amid Regulatory Delays

Key points

• Debbie Doppelt, a 60-year-old New York jeweler with lung cancer, obtained sunvozertinib from China after failing to qualify for U.S. trials; her son flew to Shanghai to procure the drug, which cost approximately $10,000.
• Sunvozertinib, developed by Dizal Pharmaceutical, was approved in China in 2023 and by the FDA in July 2025, but remained unavailable in the U.S. market as of mid-October 2026, with AstraZeneca planning a U.S. launch by early 2027.
• China now accounts for up to 46% of new drugs tested globally and leads in CAR-T cell therapy, with its first-in-human studies often proceeding faster than in the U.S. or Australia.
• The U.S. Department of Health and Human Services launched Operation TrialBlazer in June 2026 to accelerate FDA processes and reduce the need for patients to seek care abroad.
• Only about 7% of U.S. cancer patients enroll in clinical trials, leading many to seek international options, though FDA cautions that foreign treatments lack U.S. safety oversight and legal recourse.

Background

Recent coverage has highlighted broader challenges in U.S. healthcare access, including the stigma surrounding GLP-1 medications and the difficulties young patients face in balancing treatment with daily life. These issues underscore the systemic barriers that push patients toward alternative, often international, medical solutions.

How outlets are covering it

KFF Health News and Medical Daily emphasize the personal risks and regulatory gaps faced by patients traveling abroad, noting that FDA protections do not apply outside the U.S. China Daily highlights China's biotech dominance, particularly in CAR-T therapy, as a global leader. In contrast, U.S. officials and some industry leaders view the shift as a threat to national health security, while others argue that collaboration with Chinese firms is essential for curing cancer. The Washington Post, which co-published the primary story, focuses on the human impact of these regulatory delays.

Why it matters

The trend of U.S. patients seeking care in China highlights a critical gap in the American healthcare system, where regulatory delays and limited trial access force patients to take significant risks for life-saving treatments. This shift not only raises questions about the effectiveness of current FDA processes but also underscores the growing global competition in biotechnology and the potential consequences of protectionist policies in healthcare.

What to watch

AstraZeneca plans to launch sunvozertinib in the U.S. by early 2027, which may reduce the need for patients to travel abroad. Meanwhile, the FDA's Operation TrialBlazer aims to accelerate approvals, but its success remains uncertain. Patients and advocates continue to push for faster domestic access while maintaining the option to seek care in China if necessary.